Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.

1.
D’Souza
A
,
Fretham
C
,
Lee
SJ
, et al
.
Current use of and trends in hematopoietic cell transplantation in the United States
.
Biol Blood Marrow Transplant.
2020
;
26
(
8
):
e177
-
e182
.
2.
Zeiser
R
,
Blazar
BR
.
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
.
N Engl J Med.
2017
;
377
(
26
):
2565
-
2579
.
3.
Jagasia
MH
,
Greinix
HT
,
Arora
M
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report
.
Biol Blood Marrow Transplant.
2015
;
21
(
3
):
389
-
401
.
4.
Lee
SJ
,
Wolff
D
,
Kitko
C
, et al
.
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report
.
Biol Blood Marrow Transplant.
2015
;
21
(
6
):
984
-
999
.
5.
Mohamed
AJ
,
Yu
L
,
Bäckesjö
CM
, et al
.
Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
.
Immunol Rev.
2009
;
228
(
1
):
58
-
73
.
6.
Allen
JL
,
Tata
PV
,
Fore
MS
, et al
.
Increased BCR responsiveness in B cells from patients with chronic GVHD
.
Blood.
2014
;
123
(
13
):
2108
-
2115
.
7.
Dubovsky
JA
,
Beckwith
KA
,
Natarajan
G
, et al
.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
.
Blood.
2013
;
122
(
15
):
2539
-
2549
.
8.
Gomez-Rodriguez
J
,
Kraus
ZJ
,
Schwartzberg
PL
.
Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
.
FEBS J.
2011
;
278
(
12
):
1980
-
1989
.
9.
Ono
R
,
Watanabe
T
,
Kawakami
E
, et al
.
Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model
.
EBioMedicine.
2019
;
41
:
584
-
596
.
10.
Dubovsky
JA
,
Flynn
R
,
Du
J
, et al
.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
.
J Clin Invest.
2014
;
124
(
11
):
4867
-
4876
.
11.
Schutt
SD
,
Fu
J
,
Nguyen
H
, et al
.
Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice
.
PLoS One.
2015
;
10
(
9
):
e0137641
.
12.
Ryan
CE
,
Sahaf
B
,
Logan
AC
, et al
.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
.
Blood.
2016
;
128
(
25
):
2899
-
2908
.
13.
FDA expands ibrutinib indications to chronic GVHD. Available at: https://wwwfdagov/drugs/resources-information-approved-drugs/fda-expands-ibrutinib-indications-chronic-gvhd. Accessed 15 January 2022.
14.
Waller
EK
,
Miklos
D
,
Cutler
C
, et al
.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study
.
Biol Blood Marrow Transplant.
2019
;
25
(
10
):
2002
-
2007
.
15.
Miklos
D
,
Zaid
MA
,
Cooney
JP
, et al
.
Ibrutinib vs placebo in combination with corticosteroids in patients with new-onset chronic graft-versus-host disease (cGVHD): results from the randomized, double-blind phase 3 INTEGRATE study
.
EHA Library.
2021
;
324643
:
235
.
16.
Zanin-Zhorov
A
,
Weiss
JM
,
Nyuydzefe
MS
, et al
.
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism
.
Proc Natl Acad Sci USA.
2014
;
111
(
47
):
16814
-
16819
.
17.
Flynn
R
,
Paz
K
,
Du
J
, et al
.
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism
.
Blood.
2016
;
127
(
17
):
2144
-
2154
.
18.
Jagasia
M
,
Lazaryan
A
,
Bachier
CR
, et al
.
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
.
J Clin Oncol.
2021
;
39
(
17
):
1888
-
1898
.
19.
Cutler
C
,
Lee
SJ
,
Arai
S
, et al
.
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
.
Blood.
2021
;
138
(
22
):
2278
-
2289
.
20.
FDA approves belumosudil for chronic graft-versus-host disease. Available at: https://wwwfdagov/drugs/resources-information-approved-drugs/fda-approves-belumosudil-chronic-graft-versus-host-disease. Accessed 15 January 2022.
21.
Zeiser
R
,
Blazar
BR
.
Acute graft-versus-host disease: biologic process, prevention, and therapy
.
N Engl J Med.
2017
;
377
(
22
):
2167
-
2179
.
22.
Spoerl
S
,
Mathew
NR
,
Bscheider
M
, et al
.
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
.
Blood.
2014
;
123
(
24
):
3832
-
3842
.
23.
Stickel
N
,
Hanke
K
,
Marschner
D
, et al
.
MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation
.
Leukemia.
2017
;
31
(
12
):
2732
-
2741
.
24.
Hülsdünker
J
,
Ottmüller
KJ
,
Neeff
HP
, et al
.
Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset
.
Blood.
2018
;
131
(
16
):
1858
-
1869
.
25.
Zeiser
R
,
Burchert
A
,
Lengerke
C
, et al
.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
.
Leukemia.
2015
;
29
(
10
):
2062
-
2068
.
26.
Zeiser
R
,
Polverelli
N
,
Ram
R
, et al;
REACH3 Investigators
.
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
.
N Engl J Med.
2021
;
385
(
3
):
228
-
238
.
27.
FDA approves ruxolitinib for chronic graft-versus-host disease. Available at: https://wwwfdagov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease. Accessed 15 January 2022.
28.
Maas-Bauer
K
,
Kiote-Schmidt
C
,
Bertz
H
, et al
.
Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease
.
Bone Marrow Transplant.
2021
;
56
(
4
):
909
-
916
.
29.
Alexander
KA
,
Flynn
R
,
Lineburg
KE
, et al
.
CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease
.
J Clin Invest.
2014
;
124
(
10
):
4266
-
4280
.
30.
Zhang
Y
,
Shen
L
,
Dreißigacker
K
, et al
.
Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease
.
Blood.
2021
;
137
(
17
):
2403
-
2416
.
31.
DeFilipp
Z
,
Couriel
DR
,
Lazaryan
A
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2020 treatment of chronic GVHD report
.
Transplant Cell Ther.
2021
;
27
(
9
):
729
-
737
.
32.
Wolff
D
,
Radojcic
V
,
Lafyatis
R
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 highly morbid forms report
.
Transplant Cell Ther.
2021
;
27
(
10
):
817
-
835
.
33.
Williams
KM
,
Inamoto
Y
,
Im
A
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2020 etiology and prevention working group report
.
Transplant Cell Ther.
2021
;
27
(
6
):
452
-
466
.
34.
Kitko
CL
,
Pidala
J
,
Schoemans
HM
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report
.
Transplant Cell Ther.
2021
;
27
(
7
):
545
-
557
.
35.
Pidala
J
,
Kitko
C
,
Lee
SJ
, et al
.
National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIb. The 2020 preemptive therapy working group report
.
Transplant Cell Ther.
2021
;
27
(
8
):
632
-
641
.
You do not currently have access to this content.

Sign in via your Institution